Drexel Hill, PA, United States of America

Michael J Breslin

USPTO Granted Patents = 20 (Patent Applications = 7)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 8 (Patent Applications = 13)

Average Co-Inventor Count = 5.9

ph-index = 6

Forward Citations = 213(Granted Patents)

Location History:

Harleysville, PA (US) (2014)
West Point, PA (US) (2014)
Drexel Hill, PA (US) (1996 - 2022)

Company Filing History:

12 out of 2,405

Merck Sharp + Dohme Corp.

Merch Sharp & Dohme Ltd

patents

where one patent can have more than one assignee

Years Active: 1996-2025

Loading Chart...

20 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12344595 - 2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors (2025-07-01),

2. 12331018 - Pyrrolidine orexin receptor agonists (2025-06-17),

3. 12195445 - 2-amino-N-heteroaryl-nicotinamides as Na1.8 inhibitors (2025-01-14),

4. 11377438 - 2-amino-n-heteroaryl-nicotinamides as Na1.8 inhibitors (2022-07-05),

5. 8975261 - Aryloxmethyl cyclopropane derivatives as PDE10 inhibitors (2015-03-10),

6. 8710076 - 2,5-disubstituted piperidine orexin receptor antagonists (2014-04-29),

7. 8691827 - Amino tetrahydro-pyridopyrimidine PDE10 inhibitors (2014-04-08),

8. 8669272 - 2,5-disubstituted piperidine orexin receptor antagonists (2014-03-11),

9. 8569311 - Pyridyl piperidine orexin receptor antagonists (2013-10-29),

10. 8492392 - Alkoxy tetrahydro-pyridopyrimidine PDE10 inhibitors (2013-07-23),

11. 8349830 - Aryl aminopyridine PDE10 inhibitors (2013-01-08),

12. 7951797 - Substituted diazepan orexin receptor antagonists (2011-05-31),

13. 7745639 - Mitotic kinesin inhibitors (2010-06-29),

14. 7595337 - Mitotic kinesin inhibitors (2009-09-29),

15. 7235580 - Mitotic kinesin inhibitors (2007-06-26),

Title: The Innovative Contributions of Michael J Breslin

Introduction

Michael J Breslin, a prominent inventor located in Drexel Hill, PA, has made significant strides in the field of pharmaceutical innovations. With an impressive portfolio of 18 patents, his work primarily focuses on creating novel compounds that address various medical challenges, particularly those related to pain and discomfort.

Latest Patents

Among his most recent inventions are the 2-amino-N-heteroaryl-nicotinamides, which serve as Na1.8 inhibitors. These novel compounds have the potential to inhibit Na1.8 channel activity and could be beneficial in treating, preventing, managing, ameliorating, controlling, and suppressing diseases linked to Na1.8 channel activity. The implications of these compounds are particularly noteworthy, as they may be useful in addressing pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

Career Highlights

Michael J Breslin has had a distinguished career, with notable contributions while working at Merck Sharp & Dohme Corporation and Merck & Company, Inc. His expertise in medicinal chemistry and pharmacology has positioned him as a key figure in the development of innovative solutions for complex health issues.

Collaborations

Throughout his career, Breslin has collaborated with several esteemed individuals, including coworkers Christopher D Cox and Paul J Coleman. These partnerships have facilitated the exchange of ideas and advanced the research efforts in the pharmaceutical domain.

Conclusion

Michael J Breslin's contributions to innovation in the field of pharmaceuticals highlight the profound impact that dedicated inventors can have on society. His continued work on Na1.8 inhibitors reflects a commitment to addressing significant medical conditions, paving the way for potential therapeutic advancements. The future looks promising with inventive minds like Breslin driving progress in healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.